Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Less frequent azacitidine in elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia
ACTRN12613000358741Phase 4Not yet recruiting
- Sponsor
- Illawarra Private Cancer Care Centre
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Illawarra Private Cancer Care Centre. Primary endpoint: Mean survival percentage. Planned start Apr 2013; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12613000358741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000358741.